Oct 24 (Reuters) – Parabilis Medicines Inc: * PARABILIS MEDICINES PRESENTS UPDATED PHASE 1/2 DATA FOR ZOLUCATETIDE DEMONSTRATING COMPELLING EFFICACY AND FAVORABLE SAFETY AND TOLERABILITY PROFILE IN
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Couche-Tard proposes up to $8 billion offer for Cumberland Farms, The Times reports
Oct 24 (Reuters) - Canada's Alimentation Couche-Tard proposed an offer of $7.5 billion to $8…
As AI Makes Answers Instant, Bengaluru Learning Centre Focuses on How Children Think
Learners at Tattva Swayam taking part in Swayam Vichar Manch, a forum for questioning and…
Holder Rybakina sets up Fernandez clash in Ningbo final
VIDEO SHOWS: HIGHLIGHTS OF THE SEMI-FINALS OF THE WTA 500 NINGBO OPEN RESENDING WITH SHOTLIST…
